In this sense, oral supplementation with Lactobacilluscasei in mouse models has been demonstrated to reduce skin inflammation by inhibiting IFN-γ signaling and CD8+ T hypersensitivity effector cells [57], as well as through increasing interleukin 10 (IL-10) secretion and activating FoxP3+ regulatory T cells in the skin [58]. Here, CD8A is linked to dermatitis.